Novo Nordisk Appeals TLV’s Denial of Wegovy Subsidy Over Prescription Concerns

Novo Nordisk has formally appealed the Swedish Dental and Pharmaceutical Benefits Agency’s (TLV) February 19 decision to reject subsidy for its weight-loss drug Wegovy. The TLV based its denial on concerns about doctors potentially misusing prescriptions, fearing the medication might be dispensed beyond intended patient groups, leading to excessive costs. Novo Nordisk disputes this, arguing that the medication is cost-effective for a clearly defined group—adults and children aged 12 and up with high BMI and multiple related health conditions.

Maria Eklind, Novo Nordisk Sweden’s Medical Director, emphasized that restricting prescriptions to appropriate patient segments is standard practice across healthcare and expressed confidence in Swedish doctors’ adherence to such guidelines. CEO Lene Wikkelsö highlighted the increasing obesity challenge in Sweden, where over half of adults are overweight and 17% suffer from obesity, underscoring Wegovy’s potential public health benefits in reducing disease burden.

Critics, including Professor Fredrik Nyström from Linköping University, have condemned TLV’s blanket rejection as overly cautious. Nyström suggested that better monitoring could prevent misuse instead of denying patients access altogether. Novo Nordisk has requested an extension until April 17, 2026, to elaborate their case further.

The appeal illustrates tensions between cost control, prescription oversight, and the urgent need for effective obesity treatments in Sweden’s healthcare system.